Laquinimod, a quinoline-3-carboxamide, induces type ii myeloid cells that modulate central nervous system autoimmunity

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Schulze Topphoff, Ulf ^a   Shetty, Aparna ^a   Varrin Doyer, Michel ^a   Molnarfi, Nicolas ^a,c   Sagan, Sharon A ^a   Sobel, Raymond A ^b   Nelson, Patricia A ^a   Zamvil, Scott S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; GLYCOPROTEIN P 15095; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 23; INTERLEUKIN 6; LAQUINIMOD; PLACEBO; STAT1 PROTEIN; TUMOR NECROSIS FACTOR;

ADOPTIVE TRANSFER; ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; AUTOIMMUNITY; BONE MARROW CELL; CD4+ T LYMPHOCYTE; CELL SUBPOPULATION; CELLULAR IMMUNITY; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG TARGETING; FEMALE; HISTOPATHOLOGY; IMMUNOMODULATION; IMMUNOREGULATION; IN VIVO STUDY; LYMPHOCYTE DIFFERENTIATION; MONOCYTE; MOUSE; MULTIPLE SCLEROSIS; NEUROMODULATION; NONHUMAN; PHENOTYPE; PROTEIN PHOSPHORYLATION; REGULATORY T LYMPHOCYTE; TH1 CELL; TH17 CELL; UPREGULATION;

ADMINISTRATION, ORAL; ADOPTIVE TRANSFER; ANIMALS; ANTIGEN-PRESENTING CELLS; DENDRITIC CELLS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; IMMUNOLOGIC FACTORS; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; MONOCYTES; MYELOID CELLS; QUINOLONES; T-LYMPHOCYTES; TH1 CELLS; TH17 CELLS;

ANIMALIA; MUS;

EID: 84859151160     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0033797     Document Type: Article

References (49)

1. Polman C, Barkhof F, Sandberg-Wollheim M, Linde A, Nordle O, et al. (2005) Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology 64: 987-991.
2. Comi G, Pulizzi A, Rovaris M, Abramsky O, Arbizu T, et al. (2008) Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 371: 2085-2092.
3. Bomback AS, Appel GB, (2010) Updates on the treatment of lupus nephritis. J Am Soc Nephrol 21: 2028-2035.
4. Wolinsky JS, Narayana PA, Noseworthy JH, Lublin FD, Whitaker JN, et al. (2000) Linomide in relapsing and secondary progressive MS: part II: MRI results. MRI Analysis Center of the University of Texas-Houston, Health Science Center, and the North American Linomide Investigators. Neurology 54: 1734-1741.
5. Noseworthy JH, Wolinsky JS, Lublin FD, Whitaker JN, Linde A, et al. (2000) Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. North American Linomide Investigators. Neurology 54: 1726-1733.
6. Jonsson S, Andersson G, Fex T, Fristedt T, Hedlund G, et al. (2004) Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship. J Med Chem 47: 2075-2088.
7. Comi G, Abramsky O, Arbizu T, Boyko A, Gold R, et al. (2010) Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study. Mult Scler 16: 1360-1366.
8. Brunmark C, Runstrom A, Ohlsson L, Sparre B, Brodin T, et al. (2002) The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J Neuroimmunol 130: 163-172.
9. Wegner C, Stadelmann C, Pfortner R, Raymond E, Feigelson S, et al. (2010) Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis. J Neuroimmunol 227: 133-143.
10. Bruck W, Wegner C, (2011) Insight into the mechanism of laquinimod action. J Neurol Sci 306: 173-179.
11. Runstrom A, Leanderson T, Ohlsson L, Axelsson B, (2006) Inhibition of the development of chronic experimental autoimmune encephalomyelitis by laquinimod (ABR-215062) in IFN-beta k.o. and wild type mice. Journal of Neuroimmunology 173: 69-78.
12. Yang JS, Xu LY, Xiao BG, Hedlund G, Link H, (2004) Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats. J Neuroimmunol 156: 3-9.
13. Guo B, Chang EY, Cheng G, (2008) The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice. J Clin Invest 118: 1680-1690.
14. Prinz M, Schmidt H, Mildner A, Knobeloch KP, Hanisch UK, et al. (2008) Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. Immunity 28: 675-686.
15. Prod'homme T, Zamvil SS, (2008) Bench to bedside: tempering antigen-presenting cells in multiple sclerosis. Nat Med 14: 614-615.
16. Kim HJ, Ifergan I, Antel JP, Seguin R, Duddy M, et al. (2004) Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis. J Immunol 172: 7144-7153.
17. Weber MS, Prod'homme T, Youssef S, Dunn SE, Rundle CD, et al. (2007) Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat Med 13: 935-943.
18. Abdul-Majid KB, Jirholt J, Stadelmann C, Stefferl A, Kjellen P, et al. (2000) Screening of several H-2 congenic mouse strains identified H-2(q) mice as highly susceptible to MOG-induced EAE with minimal adjuvant requirement. J Neuroimmunol 111: 23-33.
19. Codarri L, Gyulveszi G, Tosevski V, Hesske L, Fontana A, et al. (2011) RORγt drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat Immunol 12: 560-567.
20. El-Behi M, Ciric B, Dai H, Yan Y, Cullimore M, et al. (2011) The encephalitogenicity of T(H)17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF. Nat Immunol 12: 568-575.
21. Brunmark C, Runstrom A, Ohlsson L, Sparre B, Brodin T, et al. (2002) The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J Neuroimmunol 130: 163-172.
22. Vremec D, Pooley J, Hochrein H, Wu L, Shortman K, (2000) CD4 and CD8 expression by dendritic cell subtypes in mouse thymus and spleen. J Immunol 164: 2978-2986.
23. Shortman K, Liu YJ, (2002) Mouse and human dendritic cell subtypes. Nat Rev Immunol 2: 151-161.
24. Yang JS, Xu LY, Xiao BG, Hedlund G, Link H, (2004) Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats. J Neuroimmunol 156: 3-9.
25. Zhu B, Bando Y, Xiao S, Yang K, Anderson AC, et al. (2007) CD11b+Ly-6C(hi) suppressive monocytes in experimental autoimmune encephalomyelitis. J Immunol 179: 5228-5237.
26. Apolloni E, Bronte V, Mazzoni A, Serafini P, Cabrelle A, et al. (2000) Immortalized myeloid suppressor cells trigger apoptosis in antigen-activated T lymphocytes. J Immunol 165: 6723-6730.
27. Serafini P, Borrello I, Bronte V, (2006) Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 16: 53-65.
28. Weber MS, Starck M, Wagenpfeil S, Meinl E, Hohlfeld R, et al. (2004) Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo. Brain 127: 1370-1378.
29. O'Shea JJ, Murray PJ, (2008) Cytokine signaling modules in inflammatory responses. Immunity 28: 477-487.
30. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, et al. (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45: 1268-1276.
31. Hennecke J, Wiley DC, (2001) T cell receptor-MHC interactions up close. Cell 104: 1-4.
32. Neuhaus O, Farina C, Yassouridis A, Wiendl H, Then Bergh F, et al. (2000) Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. Proc Natl Acad Sci U S A 97: 7452-7457.
33. Duda PW, Schmied MC, Cook SL, Krieger JI, Hafler DA, (2000) Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J Clin Invest 105: 967-976.
34. Dhib-Jalbut S, (2002) Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis. Neurology 58: S3-9.
35. Aharoni R, Teitelbaum D, Sela M, Arnon R, (1997) Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 94: 10821-10826.
36. Aharoni R, Teitelbaum D, Leitner O, Meshorer A, Sela M, et al. (2000) Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1. Proc Natl Acad Sci U S A 97: 11472-11477.
37. Comi G, Pulizzi A, Rovaris M, (2011) Oral Laquinimod reduced relapse rate and delayed progression of disability in ALLEGRO, a placebo-controlled phase III trial for relapsing-remitting multiple sclerosis. American Academy of Neurology. Honolulu, HA, USA.
38. Vollmer TL, Sörensen PS, Arnold DL on behalf of the BRAVO Study Group (2011) A placebo-controlled and active comparator phase III trial (BRAVO) for relapsing remitting multiple sclerosis. ECTRIMS (European Committee for Treatment and Research in Multiple Sclerosis). Amsterdam, The Netherlands.
39. Weiner HL, (2009) The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease? Ann Neurol 65: 239-248.
40. Thone J, Ellrichmann G, Seubert S, Peruga I, Lee DH, et al. (2012) Modulation of Autoimmune Demyelination by Laquinimod via Induction of Brain-Derived Neurotrophic Factor. A J Path 180: 267-274.
41. Linker RA, Lee DH, Demir S, Wiese S, Kruse N, et al. (2010) Functional role of brain-derived neurotrophic factor in neuroprotective autoimmunity: therapeutic implications in a model of multiple sclerosis. Brain 133: 2248-2263.
42. Bjork P, Bjork A, Vogl T, Stenstrom M, Liberg D, et al. (2009) Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides. PLoS Biol 7: e97.
43. Xiao ZY, Zhou WX, Zhang YX, Cheng JP, He JF, et al. (2007) Inhibitory effect of linomide on lipopolysaccharide-induced proinflammatory cytokine tumor necrosis factor-alpha production in RAW264.7 macrophages through suppression of NF-kappaB, p38, and JNK activation. Immunol Lett 114: 81-85.
44. Ma CJ, Ni L, Zhang Y, Zhang CL, Wu XY, et al. (2011) PD-1 negatively regulates interleukin-12 expression by limiting STAT-1 phosphorylation in monocytes/macrophages during chronic hepatitis C virus infection. Immunology 132: 421-431.
45. Guzzo C, Che Mat NF, Gee K, (2010) Interleukin-27 induces a STAT1/3- and NF-kappaB-dependent proinflammatory cytokine profile in human monocytes. J Biol Chem 285: 24404-24411.
46. Thomas KE, Galligan CL, Newman RD, Fish EN, Vogel SN, (2006) Contribution of interferon-beta to the murine macrophage response to the toll-like receptor 4 agonist, lipopolysaccharide. J Biol Chem 281: 31119-31130.
47. Schulze-Topphoff U, Prat A, Prozorovski T, Siffrin V, Paterka M, et al. (2009) Activation of kinin receptor B1 limits encephalitogenic T lymphocyte recruitment to the central nervous system. Nat Med 15: 788-793.
48. Stuve O, Youssef S, Weber MS, Nessler S, von Budingen HC, et al. (2006) Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity. J Clin Invest 116: 1037-1044.
49. Kuchroo VK, Das MP, Brown JA, Ranger AM, Zamvil SS, et al. (1995) B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 80: 707-718.